SKIL and breast carcinoma: Thus, SnON may normally repress TGF-β signalling but relocalises to the cytoplasm in more invasive breast cancer, and our data suggest that this may be driven by other paracrine signals, including crosstalk between TGF-β signalling and other pathways.